Kumar Chandra C, Madison Vincent
Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Oncogene. 2005 Nov 14;24(50):7493-501. doi: 10.1038/sj.onc.1209087.
AKT kinases are attractive targets for small molecule drug discovery because of their key role in tumor cell survival/proliferation and their overexpression/activation in many human cancers. This review summarizes studies that support the rationale for targeting AKT kinases in new drug discovery efforts. Structural features of AKT kinase in its inactive and active states, as determined by crystal structure analysis, are described. Recent efforts in the development and biological evaluation of small molecule inhibitors of AKT, and the challenges remaining are summarized. Inhibitors targeting the ATP binding site, PH domain and protein substrate binding site, as well as isoform selective allosteric inhibitors are reviewed. Structure-based design using PKA mutants as surrogates and computer modeling in the discovery of selective inhibitors is discussed. The issues and challenges facing the development of different classes of inhibitors as therapeutics are also discussed.
AKT激酶因其在肿瘤细胞存活/增殖中的关键作用以及在许多人类癌症中的过表达/激活,成为小分子药物研发的有吸引力的靶点。本综述总结了支持在新药研发中靶向AKT激酶的理论依据的研究。描述了通过晶体结构分析确定的AKT激酶处于非活性和活性状态时的结构特征。总结了近期在AKT小分子抑制剂的开发和生物学评估方面的努力以及仍然存在的挑战。综述了靶向ATP结合位点、PH结构域和蛋白质底物结合位点的抑制剂,以及亚型选择性变构抑制剂。讨论了使用PKA突变体作为替代物的基于结构的设计以及计算机建模在发现选择性抑制剂中的应用。还讨论了将不同类型抑制剂开发为治疗药物所面临的问题和挑战。